By Anthony O. Goriainoff 



  AstraZeneca PLC said Tuesday that Imfinzi has been approved in the EU for the treatment of small cell lung cancer in adults in combination with a choice of chemotherapies. 


  The British pharmaceuticals giant said the approval was based on positive results from the Phase 3 CASPIAN trial. The trial showed Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful overall survival benefit for the first-line treatment of patients with small cell lung cancer, also known as ES-SCLC. 


  "Imfinzi in combination with etoposide and either carboplatin or cisplatin is also approved in the U.S., Japan and several other countries for the treatment of ES-SCLC in the first-line setting and is currently under regulatory review in other countries," the company said. 


  AstraZeneca said separately that its renal drug Farxiga has been proven to significantly prolong the survival of patients with chronic kidney disease with and without type-2 diabetes. "Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type-2 diabetes, and reduce the risk of hospitalization for heart failure and nephropathy in type-2 diabetes," it said. 


  Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com